Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient

Fadi Farhat, Mohammad Tarabaih, Ali Kanj, Majeda Aoun, Joseph Kattan, Tarek Assi, Ahmad Awada

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

11 Citations (Scopus)

Résumé

CDK4/6 inhibitors in association with aromatase inhibitors have led to a paradigm shift in the management of metastatic positive hormone-receptors breast cancer. Liver toxicity is common with these agents, but no data are reported on the sequential use of these CDK4/6 inhibitors in case of confirmed efficacy and intolerable toxicity. In this article, we report the successful use of Palbociclib in a metastatic positive hormone-receptors breast cancer patient after initial response to Ribociclib, which was interrupted for grade 4 liver toxicity.

langue originaleAnglais
Pages (de - à)85-89
Nombre de pages5
journalAnti-Cancer Drugs
Volume31
Numéro de publication1
Les DOIs
étatPublié - 1 janv. 2020
Modification externeOui

Contient cette citation